Details of the Drug

General Information of Drug (ID: DM2NUH3)

Drug Name

Imipramine

Synonyms

Antideprin; Berkomine; Censtim; Censtin; Declomipramine; Dimipressin; Dpid; Dynaprin; Eupramin; Imavate; Imidobenzyle; Imipramin; Imipramina; Imipraminum; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Janimine; Melipramin; Melipramine; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; Surplix; Timolet; Tofranil; Imipramina [Italian]; Tofraniln A; Antideprin (TN); Deprimin (TN); Deprinol (TN); Depsonil (TN); Dyna-zina; Dynaprin (TN); Eupramin (TN); G-22355; Imipramil (TN); Imipramina [INN-Spanish]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum [INN-Latin]; Irmin (TN); Janimine (TN); Janimine (hydrochloride); Melipramin (TN); SK-Pramine; Surplix (TN); Tofranil(TN); Tofranil (free base); Tofranil (hydrochloride); Tofranil, base; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI)

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Nocturia	MF55	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

280.4

Logarithm of the Partition Coefficient (xlogp)

4.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-1.5 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 62% [3]
Clearance: The clearance of drug is 1 L/h/kg [5]
Elimination: Imipramine is primarily excreted in the urine with less than 5% present as the parent compound [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 12 hours [5]
Metabolism: The drug is metabolized via the liver [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.0944 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.075% [7]
Vd: The volume of distribution (Vd) of drug is 10-20 L/kg [5]

Chemical Identifiers

Formula: C19H24N2
IUPAC Name: 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
Canonical SMILES: CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
InChI: InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
InChIKey: BCGWQEUPMDMJNV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3696
ChEBI ID: CHEBI:47499
CAS Number: 50-49-7
DrugBank ID: DB00458
TTD ID: D06ZUK
VARIDT ID: DR00552
INTEDE ID: DR0861
ACDINA ID: D00325

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[12]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[13]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[14]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[14]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[15]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[14]
Docosahexaenoic acid omega-hydroxylase (CYP4F11)	DEIZLTN	CP4FB_HUMAN	Substrate	[16]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Gene/Protein Processing	[17]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[18]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[19]
Alpha-1-acid glycoprotein 2 (ORM2)	OTRJGZP8	A1AG2_HUMAN	Protein Interaction/Cellular Processes	[20]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[18]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[21]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[18]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Gene/Protein Processing	[22]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[23]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[23]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Depression

ICD Disease Classification

6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Norepinephrine transporter (NET)	DTT	SLC6A2	7.05E-01	7.02E-03	0.07
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.83E-01	4.69E-02	1.89E-01
Cytochrome P450 2C18 (CYP2C18)	DME	CYP2C18	7.90E-01	3.72E-02	2.95E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	1.87E-01	4.98E-02	3.61E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	5.79E-01	-1.30E-02	-9.78E-02
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.68E-01	3.64E-02	2.72E-01
Docosahexaenoic acid omega-hydroxylase (CYP4F11)	DME	CYP4F11	6.86E-01	-4.38E-02	-2.46E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	7.66E-01	9.19E-03	4.88E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Imipramine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Imipramine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[24]
Fluoxetine	DM3PD2C	Major	Decreased metabolism of Imipramine caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[25]
Nortriptyline	DM4KDYJ	Moderate	Additive anticholinergic effects by the combination of Imipramine and Nortriptyline.	Depression [6A70-6A7Z]	[26]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Imipramine and Vilazodone.	Depression [6A70-6A7Z]	[24]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Imipramine and Nefazodone.	Depression [6A70-6A7Z]	[24]
Paroxetine	DM5PVQE	Major	Decreased metabolism of Imipramine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[27]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Imipramine and Selegiline.	Depression [6A70-6A7Z]	[28]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Imipramine and Vortioxetine.	Depression [6A70-6A7Z]	[24]
Duloxetine	DM9BI7M	Major	Additive serotonergic effects by the combination of Imipramine and Duloxetine.	Depression [6A70-6A7Z]	[24]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Imipramine and Isocarboxazid.	Depression [6A70-6A7Z]	[28]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Imipramine and Milnacipran.	Depression [6A70-6A7Z]	[24]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Imipramine and Escitalopram.	Depression [6A70-6A7Z]	[29]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Imipramine and Tranylcypromine.	Depression [6A70-6A7Z]	[28]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Imipramine and Desvenlafaxine.	Depression [6A70-6A7Z]	[24]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Imipramine and OPC-34712.	Depression [6A70-6A7Z]	[26]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Imipramine and Phenelzine.	Depression [6A70-6A7Z]	[28]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Imipramine and Clomipramine.	Depression [6A70-6A7Z]	[26]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Imipramine and Trazodone.	Depression [6A70-6A7Z]	[24]
Amoxapine	DMKITQE	Moderate	Additive anticholinergic effects by the combination of Imipramine and Amoxapine.	Depression [6A70-6A7Z]	[26]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Imipramine and Doxepin.	Depression [6A70-6A7Z]	[26]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Imipramine and Maprotiline.	Depression [6A70-6A7Z]	[26]
-----------


⏷ Show the Full List of 21 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Imipramine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Imipramine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[28]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Imipramine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[30]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Midostaurin.	Acute myeloid leukaemia [2A60]	[31]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Idarubicin.	Acute myeloid leukaemia [2A60]	[31]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[31]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Arn-509.	Acute myeloid leukaemia [2A60]	[32]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[33]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Imipramine and Oliceridine.	Acute pain [MG31]	[34]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Imipramine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[26]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Imipramine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[35]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Imipramine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[35]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Imipramine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[26]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Imipramine and Memantine.	Alzheimer disease [8A20]	[26]
Galantamine	DMEO794	Moderate	Antagonize the effect of Imipramine when combined with Galantamine.	Alzheimer disease [8A20]	[36]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Imipramine when combined with Rivastigmine.	Alzheimer disease [8A20]	[36]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Imipramine when combined with Donepezil.	Alzheimer disease [8A20]	[36]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Imipramine and Metronidazole.	Amoebiasis [1A36]	[37]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Imipramine and Ivabradine.	Angina pectoris [BA40]	[32]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Imipramine and Bepridil.	Angina pectoris [BA40]	[38]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Imipramine and Dronedarone.	Angina pectoris [BA40]	[31]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Imipramine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[39]
Buspirone	DMBS632	Major	Additive serotonergic effects by the combination of Imipramine and Buspirone.	Anxiety disorder [6B00-6B0Z]	[24]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Imipramine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[26]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Cilostazol.	Arterial occlusive disease [BD40]	[31]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Voriconazole.	Aspergillosis [1F20]	[31]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Imipramine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[26]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Imipramine caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[40]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[31]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Imipramine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[42]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[31]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Imipramine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[31]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Imipramine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Imipramine and Linezolid.	Bacterial infection [1A00-1C4Z]	[43]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[41]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[31]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Retigabine.	Behcet disease [4A62]	[31]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Imipramine and Cariprazine.	Bipolar disorder [6A60]	[26]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Imipramine and Loperamide.	Bowel habit change [ME05]	[44]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Lapatinib.	Breast cancer [2C60-2C6Y]	[31]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[31]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Imipramine and Toremifene.	Breast cancer [2C60-2C6Y]	[31]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Imipramine and Sotalol.	Cardiac arrhythmia [BC9Z]	[31]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Imipramine when combined with Acetylcholine.	Cataract [9B10]	[45]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[46]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Imipramine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[47]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Imipramine and Dihydrocodeine.	Chronic pain [MG30]	[34]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Imipramine and Levomilnacipran.	Chronic pain [MG30]	[24]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Oxaliplatin.	Colorectal cancer [2B91]	[31]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Imipramine and Olopatadine.	Conjunctiva disorder [9A60]	[48]
Mestranol	DMG3F94	Minor	Decreased metabolism of Imipramine caused by Mestranol.	Contraceptive management [QA21]	[49]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Halothane.	Corneal disease [9A76-9A78]	[31]
Alfentanil	DMVO0UB	Moderate	Additive CNS depression effects by the combination of Imipramine and Alfentanil.	Corneal disease [9A76-9A78]	[34]
Remifentanil	DMZTXCH	Moderate	Additive CNS depression effects by the combination of Imipramine and Remifentanil.	Corneal disease [9A76-9A78]	[34]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Probucol.	Coronary atherosclerosis [BA80]	[31]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Clofazimine.	Crohn disease [DD70]	[50]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Imipramine and Mifepristone.	Cushing syndrome [5A70]	[31]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Imipramine and Pasireotide.	Cushing syndrome [5A70]	[31]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Osilodrostat.	Cushing syndrome [5A70]	[32]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Imipramine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[51]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Imipramine and Ethanol.	Cystitis [GC00]	[52]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Imipramine and Mepenzolate.	Digestive system disease [DE2Z]	[26]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Imipramine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[53]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Imipramine and Oxybutynine.	Discovery agent [N.A.]	[26]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[31]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Imipramine and Meclizine.	Dizziness and giddiness [MB48]	[26]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Deutetrabenazine.	Dystonic disorder [8A02]	[54]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Ingrezza.	Dystonic disorder [8A02]	[55]
Fenfluramine	DM0762O	Moderate	Additive serotonergic effects by the combination of Imipramine and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[56]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Imipramine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[57]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Imipramine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[58]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Imipramine caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[59]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Imipramine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Imipramine and Solifenacin.	Functional bladder disorder [GC50]	[26]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Imipramine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[61]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Imipramine and Tolterodine.	Functional bladder disorder [GC50]	[26]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Imipramine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[62]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Imipramine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[63]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Pentamidine.	Fungal infection [1F29-1F2F]	[31]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Imipramine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[64]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Imipramine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[63]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Imipramine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[63]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Imipramine and Propantheline.	Gastric ulcer [DA60]	[26]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Imipramine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[65]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Imipramine and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[31]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[31]
Acetazolamide	DM1AF5U	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Imipramine caused by Acetazolamide mediated altered urine pH.	Glaucoma [9C61]	[66]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Imipramine when combined with Isoflurophate.	Glaucoma [9C61]	[45]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Imipramine and Brimonidine.	Glaucoma [9C61]	[67]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Imipramine when combined with Pilocarpine.	Glaucoma [9C61]	[45]
Carvedilol	DMHTEAO	Moderate	Increased plasma concentrations of Imipramine and Carvedilol due to competitive inhibition of the same metabolic pathway.	Heart failure [BD10-BD1Z]	[59]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Imipramine and Procarbazine.	Hodgkin lymphoma [2B30]	[28]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Imipramine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[69]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Imipramine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[70]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Imipramine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[71]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Imipramine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[72]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Imipramine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Imipramine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Imipramine caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[37]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Imipramine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[37]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Imipramine caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[73]
Labetalol	DMK8U72	Moderate	Increased plasma concentrations of Imipramine and Labetalol due to competitive inhibition of the same metabolic pathway.	Hypertension [BA00-BA04]	[59]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Imipramine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[74]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Imipramine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[75]
Propiomazine	DMKY8V1	Moderate	Increased plasma concentrations of Imipramine and Propiomazine due to competitive inhibition of the same metabolic pathway.	Insomnia [7A00-7A0Z]	[76]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Imipramine and ITI-007.	Insomnia [7A00-7A0Z]	[26]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Imipramine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[31]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Imipramine and Clidinium.	Irritable bowel syndrome [DD91]	[26]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Imipramine and Dicyclomine.	Irritable bowel syndrome [DD91]	[26]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Imipramine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[36]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Imipramine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[32]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Imipramine and Crizotinib.	Lung cancer [2C25]	[77]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Imipramine and Porfimer Sodium.	Lung cancer [2C25]	[78]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Imipramine and Ceritinib.	Lung cancer [2C25]	[31]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Imipramine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[79]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Imipramine and Osimertinib.	Lung cancer [2C25]	[80]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Imipramine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[81]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Imipramine and Selpercatinib.	Lung cancer [2C25]	[32]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Imipramine and Lumefantrine.	Malaria [1F40-1F45]	[37]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Imipramine and Halofantrine.	Malaria [1F40-1F45]	[82]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Imipramine and Chloroquine.	Malaria [1F40-1F45]	[83]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Quinine.	Malaria [1F40-1F45]	[31]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[32]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Imipramine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[84]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Imipramine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[85]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Imipramine and Vemurafenib.	Melanoma [2C30]	[31]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and LGX818.	Melanoma [2C30]	[86]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Imipramine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[32]
Ethinyl estradiol	DMODJ40	Minor	Decreased metabolism of Imipramine caused by Ethinyl estradiol.	Menopausal disorder [GA30]	[49]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Imipramine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[87]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Imipramine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[88]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Imipramine and Flibanserin.	Mood disorder [6A60-6E23]	[89]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Imipramine and Panobinostat.	Multiple myeloma [2A83]	[90]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Imipramine and Thalidomide.	Multiple myeloma [2A83]	[91]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Imipramine and Siponimod.	Multiple sclerosis [8A40]	[37]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Imipramine and Fingolimod.	Multiple sclerosis [8A40]	[31]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of Imipramine and Ozanimod.	Multiple sclerosis [8A40]	[92]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Imipramine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[32]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Imipramine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[31]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Imipramine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[93]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[94]
Modafinil	DMYILBE	Moderate	Decreased metabolism of Imipramine caused by Modafinil mediated inhibition of CYP450 enzyme.	Narcolepsy [7A20]	[37]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Imipramine and Phenindamine.	Nasopharyngitis [CA00]	[26]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Imipramine and Dimenhydrinate.	Nausea/vomiting [MD90]	[26]
Promethazine	DM6I5GR	Moderate	Increased plasma concentrations of Imipramine and Promethazine due to competitive inhibition of the same metabolic pathway.	Nausea/vomiting [MD90]	[76]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Imipramine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[95]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Imipramine and Cyclizine.	Nausea/vomiting [MD90]	[26]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Imipramine and Granisetron.	Nausea/vomiting [MD90]	[31]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Imipramine and Dolasetron.	Nausea/vomiting [MD90]	[31]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Imipramine and Ondansetron.	Nausea/vomiting [MD90]	[31]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Entrectinib.	Non-small cell lung cancer [2C25]	[37]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Imipramine and Sibutramine.	Obesity [5B80-5B81]	[96]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Imipramine and Lorcaserin.	Obesity [5B80-5B81]	[97]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Imipramine and Dexfenfluramine.	Obesity [5B80-5B81]	[24]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Imipramine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[32]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Lofexidine.	Opioid use disorder [6C43]	[32]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Imipramine and Apraclonidine.	Optic nerve disorder [9C40]	[98]
Valdecoxib	DMAY7H4	Minor	Decreased metabolism of Imipramine caused by Valdecoxib mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[32]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Imipramine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[37]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Imipramine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[99]
Altretamine	DMKLAYG	Moderate	Additive hypotensive effects by the combination of Imipramine and Altretamine.	Ovarian cancer [2C73]	[100]
Pentazocine	DM1XBHS	Moderate	Additive CNS depression effects by the combination of Imipramine and Pentazocine.	Pain [MG30-MG3Z]	[34]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Imipramine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[101]
Butorphanol	DM5KYPJ	Moderate	Additive CNS depression effects by the combination of Imipramine and Butorphanol.	Pain [MG30-MG3Z]	[34]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Imipramine and Oxymorphone.	Pain [MG30-MG3Z]	[34]
Aspirin	DM672AH	Moderate	Increased plasma concentration of Imipramine and Aspirin due to competitive binding of plasma proteins.	Pain [MG30-MG3Z]	[102]
Diflunisal	DM7EN8I	Moderate	Increased plasma concentration of Imipramine and Diflunisal due to competitive binding of plasma proteins.	Pain [MG30-MG3Z]	[102]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Imipramine and Levorphanol.	Pain [MG30-MG3Z]	[34]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Imipramine and Dezocine.	Pain [MG30-MG3Z]	[34]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Imipramine and Flavoxate.	Pain [MG30-MG3Z]	[26]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Imipramine and Nalbuphine.	Pain [MG30-MG3Z]	[34]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Imipramine and Buprenorphine.	Pain [MG30-MG3Z]	[34]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Imipramine and Hydrocodone.	Pain [MG30-MG3Z]	[34]
Oxycodone	DMXLKHV	Moderate	Additive CNS depression effects by the combination of Imipramine and Oxycodone.	Pain [MG30-MG3Z]	[34]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Triclabendazole.	Parasitic worm infestation [1F90]	[31]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Imipramine and Safinamide.	Parkinsonism [8A00]	[92]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Imipramine and Rasagiline.	Parkinsonism [8A00]	[28]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Imipramine and Biperiden.	Parkinsonism [8A00]	[26]
Levodopa	DMN3E57	Minor	Altered absorption of Imipramine due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[103]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Pimavanserin.	Parkinsonism [8A00]	[104]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Imipramine and Orphenadrine.	Parkinsonism [8A00]	[26]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Apomorphine.	Parkinsonism [8A00]	[31]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Imipramine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[105]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Imipramine and Methylscopolamine.	Peptic ulcer [DA61]	[26]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Famotidine.	Peptic ulcer [DA61]	[37]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Imipramine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[106]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Imipramine and Lefamulin.	Pneumonia [CA40]	[107]
Choline salicylate	DM8P137	Moderate	Increased plasma concentration of Imipramine and Choline salicylate due to competitive binding of plasma proteins.	Postoperative inflammation [1A00-CA43]	[102]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Imipramine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[108]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Degarelix.	Prostate cancer [2C82]	[32]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Imipramine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[109]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Nilutamide.	Prostate cancer [2C82]	[32]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Enzalutamide.	Prostate cancer [2C82]	[32]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Flutamide.	Prostate cancer [2C82]	[32]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Relugolix.	Prostate cancer [2C82]	[32]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Bicalutamide.	Prostate cancer [2C82]	[32]
Levomepromazine	DMIKFEL	Moderate	Increased plasma concentrations of Imipramine and Levomepromazine due to competitive inhibition of the same metabolic pathway.	Psychotic disorder [6A20-6A25]	[76]
Fluphenazine	DMIT8LX	Moderate	Increased plasma concentrations of Imipramine and Fluphenazine due to competitive inhibition of the same metabolic pathway.	Psychotic disorder [6A20-6A25]	[76]
Triflupromazine	DMKFQJP	Moderate	Increased plasma concentrations of Imipramine and Triflupromazine due to competitive inhibition of the same metabolic pathway.	Psychotic disorder [6A20-6A25]	[76]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Imipramine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[110]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Imipramine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[111]
Salsalate	DM13P4C	Moderate	Increased plasma concentration of Imipramine and Salsalate due to competitive binding of plasma proteins.	Rheumatoid arthritis [FA20]	[102]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Imipramine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[112]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Quetiapine.	Schizophrenia [6A20]	[31]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Imipramine and Mesoridazine.	Schizophrenia [6A20]	[31]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Imipramine and Thioridazine.	Schizophrenia [6A20]	[113]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Imipramine and Aripiprazole.	Schizophrenia [6A20]	[26]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Imipramine and Iloperidone.	Schizophrenia [6A20]	[31]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Paliperidone.	Schizophrenia [6A20]	[31]
Haloperidol	DM96SE0	Major	Decreased metabolism of Imipramine caused by Haloperidol mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[114]
Perphenazine	DMA4MRX	Moderate	Increased plasma concentrations of Imipramine and Perphenazine due to competitive inhibition of the same metabolic pathway.	Schizophrenia [6A20]	[76]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Imipramine and Molindone.	Schizophrenia [6A20]	[26]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Imipramine and Thiothixene.	Schizophrenia [6A20]	[26]
Trifluoperazine	DMKBYWI	Moderate	Increased plasma concentrations of Imipramine and Trifluoperazine due to competitive inhibition of the same metabolic pathway.	Schizophrenia [6A20]	[76]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Imipramine and Risperidone.	Schizophrenia [6A20]	[26]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Imipramine and Amisulpride.	Schizophrenia [6A20]	[115]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Asenapine.	Schizophrenia [6A20]	[31]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Imipramine and Pimozide.	Schizophrenia [6A20]	[32]
Salicyclic acid	DM2F8XZ	Moderate	Increased plasma concentration of Imipramine and Salicyclic acid due to competitive binding of plasma proteins.	Seborrhoeic dermatitis [EA81]	[102]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of Imipramine and Fentanyl.	Sensation disturbance [MB40]	[24]
Sufentanil	DMU7YEL	Moderate	Additive CNS depression effects by the combination of Imipramine and Sufentanil.	Sensation disturbance [MB40]	[34]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[31]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Imipramine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Imipramine caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Imipramine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[31]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Imipramine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[31]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[32]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[31]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[31]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Imipramine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[31]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Imipramine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[116]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Lenvatinib.	Thyroid cancer [2D10]	[31]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Imipramine and Cabozantinib.	Thyroid cancer [2D10]	[32]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Imipramine and Papaverine.	Tonus and reflex abnormality [MB47]	[117]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Imipramine and Tizanidine.	Tonus and reflex abnormality [MB47]	[118]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Imipramine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[110]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Tacrolimus.	Transplant rejection [NE84]	[31]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Imipramine and Atropine.	Unspecific substance harmful effect [NE6Z]	[26]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[31]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Imipramine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[26]
Methdilazine	DMAUHQX	Moderate	Increased plasma concentrations of Imipramine and Methdilazine due to competitive inhibition of the same metabolic pathway.	Vasomotor/allergic rhinitis [CA08]	[76]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Imipramine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[26]
Trimeprazine	DMEMV9D	Moderate	Increased plasma concentrations of Imipramine and Trimeprazine due to competitive inhibition of the same metabolic pathway.	Vasomotor/allergic rhinitis [CA08]	[119]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Imipramine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[26]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Imipramine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[26]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Imipramine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[26]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Imipramine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[31]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Imipramine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[120]
Flecainide	DMSQDLE	Moderate	Decreased metabolism of Imipramine caused by Flecainide mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[120]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Imipramine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[31]
-----------


⏷ Show the Full List of 255 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 30	E00456	3000709	Colorant
Docusate sodium	E00563	23673837	Surfactant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
methylparaben	E00149	7456	Antimicrobial preservative
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Calcium phosphate	E00298	24456	Anticaking agent; Buffering agent; Desiccant; Diluent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Ferrous oxide	E00241	14945	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Imipramine 100 mg capsule	100 mg	Oral Capsule	Oral
Imipramine 125 mg capsule	125 mg	Oral Capsule	Oral
Imipramine 150 mg capsule	150 mg	Oral Capsule	Oral
Imipramine 75 mg capsule	75 mg	Oral Capsule	Oral
Imipramine 25 mg tablet	25 mg	Oral Tablet	Oral
Imipramine 50 mg tablet	50 mg	Oral Tablet	Oral
Imipramine 10 mg tablet	10 mg	Oral Tablet	Oral
Imipramine Hydrochloride 10mg tablet	10mg	Tablet	Oral
Imipramine Hydrochloride 25mg tablet	25mg	Tablet	Oral
Imipramine Hydrochloride 50mg tablet	50mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 357).
2	Imipramine FDA Label
3	FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use
4	BDDCS applied to over 900 drugs
5	Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet. 1990 May;18(5):346-64.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
9	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
10	Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
11	QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6.
12	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
13	Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7.
14	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
15	Catalysis of drug oxidation during embryogenesis in human hepatic tissues using imipramine as a model substrate. Drug Metab Dispos. 1999 Nov;27(11):1306-8.
16	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
17	Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. Toxicol Lett. 2015 Feb 3;232(3):557-65.
18	A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
19	Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
20	Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004.
21	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
22	Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
23	Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
24	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
25	Aranow AB, Hudson JI, Pope HG, et al "Elevated antidepressant plasma levels after addition of fluoxetine." Am J Psychiatry 146 (1989): 911-3. [PMID: 2787124]
26	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
27	Albers LJ, Reist C, Helmeste D, Vu R, Tang SW "Paroxetine shifts imipramine metabolism." Psychiatry Res 59 (1996): 189-96. [PMID: 8930024]
28	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
29	Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
30	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
31	Canadian Pharmacists Association.
32	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
34	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
35	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
36	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
37	Cerner Multum, Inc. "Australian Product Information.".
38	Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
39	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
40	Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
41	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
42	Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
43	Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
44	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
45	Multum Information Services, Inc. Expert Review Panel.
46	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
47	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
48	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
49	Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
50	Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
51	Cerner Multum, Inc. "Canadian Product Information.".
52	Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
53	Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
54	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
55	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
56	Fogelson DL "Fenfluramine and the cytochrome P450 system." Am J Psychiatry 154 (1997): 436-7. [PMID: 9054800]
57	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
58	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
59	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
60	Brosen K, Kragh-Sorensen P "Concomitant intake of nortriptyline and carbamazepine." Ther Drug Monit 15 (1993): 258-60. [PMID: 8333008]
61	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
62	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
63	Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9. [PMID: 10750939]
64	AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
65	Abernethy DR, Greenblatt DJ, Shader RI "Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability." J Pharmacol Exp Ther 229 (1984): 702-5. [PMID: 6726654]
66	Gram LF, Kofod B, Christiansen J, Rafaelsen OJ "Imipramine metabolism: pH-dependent distribution and urinary excretion." Clin Pharmacol Ther 12 (1971): 239-44. [PMID: 5554940]
67	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
68	Eap CB, Bender S, Gastpar M, et al "Steady state plasma levels of the enantiomers of trimipramine and its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients." Ther Drug Monit 22 (2000): 209-14. [PMID: 10774635]
69	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
70	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
71	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
72	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
73	Hermann DJ, Krol TF, Dukes GE, et al "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine." J Clin Pharmacol 32 (1992): 176-83. [PMID: 1613128]
74	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
75	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
76	Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
77	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
78	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
79	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
80	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
81	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
82	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
83	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
84	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
85	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
86	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
87	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
88	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
89	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
90	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
91	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
92	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
93	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
94	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
95	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
96	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
97	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
98	Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
99	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
100	Bruckner HW, Schleifer SJ "Orthostatic hypotension as a complication of hexamethylmelamine antidepressant interaction." Cancer Treat Rep 67 (1983): 516. [PMID: 6406063]
101	Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
102	Juarez-Olguin H, Jung-Cook H, Flores-Perez J, Asseff IL "Clinical Evidence of an Interaction Between Imipramine and Acetylsalicylic Acid on Protein Binding in Depressed Patients." Clin Neuropharmacol 25 (2002): 32-36. [PMID: 11852294]
103	Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
104	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
105	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
106	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
107	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
108	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
109	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
110	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
111	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
112	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
113	Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
114	Alter P, Tontsch D, Grimm W "Doxepin-induced torsade de pointes tachycardia." Ann Intern Med 135 (2001): 384-5. [PMID: 11529713]
115	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
116	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
117	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
118	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
119	Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
120	Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]